RDN-929 / Alkermes - LARVOL DELTA

A 28 Day Parallel Group Study to Assess the Effects of RDN-929 (clinicaltrials.gov) - P1; N=7; Terminated; Sponsor: Alkermes, Inc.; N=25 ➔ 7; Recruiting ➔ Terminated; Participants no longer receiving intervention

Enrollment change • Trial termination

SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RDN-929: A POTENT AND SELECTIVE HDAC-COREST COMPLEX INHIBITOR FOR THE TREATMENT OF SYNAPTOPATHIES. (CTAD 2019) - "RDN-929 administered orally as a single dose up to 500 mg and multiple daily doses up to 300 mg in healthy young males and healthy older males and females demonstrates an excellent safety, tolerability and PK profile. The significant increases observed in PBMC histone acetylation con rm peripheral target engagement. These initial data suggest that RDN-929 represents a novel, brain-penetrant, complex-selective HDAC inhibitor with a safety profile that is supportive of further clinical development in patient populations characterized by synaptic loss or dysfunction."

Clinical • PK/PD data

A 28 Day Parallel Group Study to Assess the Effects of RDN-929 (clinicaltrials.gov) - P1; N=25; Recruiting; Sponsor: Rodin Therapeutics; Trial completion date: Sep 2019 ➔ Dec 2019; Trial primary completion date: Sep 2019 ➔ Dec 2019

Clinical • Trial completion date • Trial primary completion date